These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35120593)

  • 1. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
    Shah SJ; Borlaug BA; Chung ES; Cutlip DE; Debonnaire P; Fail PS; Gao Q; Hasenfuß G; Kahwash R; Kaye DM; Litwin SE; Lurz P; Massaro JM; Mohan RC; Ricciardi MJ; Solomon SD; Sverdlov AL; Swarup V; van Veldhuisen DJ; Winkler S; Leon MB;
    Lancet; 2022 Mar; 399(10330):1130-1140. PubMed ID: 35120593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II.
    Gustafsson F; Petrie MC; Komtebedde J; Swarup V; Winkler S; Hasenfuß G; Borlaug BA; Mohan RC; Flaherty JD; Sverdlov AL; Fail PS; Chung ES; Lurz P; Lilly S; Kaye DM; Cleland JGF; Cikes M; Leon MB; Cutlip DE; van Veldhuisen DJ; Solomon SD; Shah SJ
    JACC Heart Fail; 2024 Aug; 12(8):1425-1438. PubMed ID: 38934964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
    Borlaug BA; Blair J; Bergmann MW; Bugger H; Burkhoff D; Bruch L; Celermajer DS; Claggett B; Cleland JGF; Cutlip DE; Dauber I; Eicher JC; Gao Q; Gorter TM; Gustafsson F; Hayward C; van der Heyden J; Hasenfuß G; Hummel SL; Kaye DM; Komtebedde J; Massaro JM; Mazurek JA; McKenzie S; Mehta SR; Petrie MC; Post MC; Nair A; Rieth A; Silvestry FE; Solomon SD; Trochu JN; Van Veldhuisen DJ; Westenfeld R; Leon MB; Shah SJ;
    Circulation; 2022 May; 145(21):1592-1604. PubMed ID: 35354306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial.
    Feldman T; Mauri L; Kahwash R; Litwin S; Ricciardi MJ; van der Harst P; Penicka M; Fail PS; Kaye DM; Petrie MC; Basuray A; Hummel SL; Forde-McLean R; Nielsen CD; Lilly S; Massaro JM; Burkhoff D; Shah SJ;
    Circulation; 2018 Jan; 137(4):364-375. PubMed ID: 29142012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial.
    Patel RB; Silvestry FE; Komtebedde J; Solomon SD; Hasenfuß G; Litwin SE; Borlaug BA; Price MJ; Kawash R; Hummel SL; Cutlip DE; Leon MB; van Veldhuisen DJ; Rieth AJ; McKenzie S; Bugger H; Mazurek JA; Kapadia SR; Vanderheyden M; Ky B; Shah SJ
    JAMA Cardiol; 2024 Jun; 9(6):507-522. PubMed ID: 38630494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial.
    Shah SJ; Feldman T; Ricciardi MJ; Kahwash R; Lilly S; Litwin S; Nielsen CD; van der Harst P; Hoendermis E; Penicka M; Bartunek J; Fail PS; Kaye DM; Walton A; Petrie MC; Walker N; Basuray A; Yakubov S; Hummel SL; Chetcuti S; Forde-McLean R; Herrmann HC; Burkhoff D; Massaro JM; Cleland JGF; Mauri L
    JAMA Cardiol; 2018 Oct; 3(10):968-977. PubMed ID: 30167646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.
    Hasenfuß G; Hayward C; Burkhoff D; Silvestry FE; McKenzie S; Gustafsson F; Malek F; Van der Heyden J; Lang I; Petrie MC; Cleland JG; Leon M; Kaye DM;
    Lancet; 2016 Mar; 387(10025):1298-304. PubMed ID: 27025436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).
    Berry N; Mauri L; Feldman T; Komtebedde J; van Veldhuisen DJ; Solomon SD; Massaro JM; Shah SJ
    Am Heart J; 2020 Aug; 226():222-231. PubMed ID: 32629295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial.
    Hasenfuss G; Gustafsson F; Kaye D; Shah SJ; Burkhoff D; Reymond MC; Komtebedde J; Hünlich M;
    J Card Fail; 2015 Jul; 21(7):594-600. PubMed ID: 26055211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction.
    Litwin SE; Komtebedde J; Hu M; Burkhoff D; Hasenfuß G; Borlaug BA; Solomon SD; Zile MR; Mohan RC; Khawash R; Sverdlov AL; Fail P; Chung ES; Kaye DM; Blair J; Eicher JC; Hummel SL; Zirlik A; Westenfeld R; Hayward C; Gorter TM; Demers C; Shetty R; Lewis G; Starling RC; Patel S; Gupta DK; Morsli H; Penicka M; Cikes M; Gustafsson F; Silvestry FE; Rowin EJ; Cutlip DE; Leon MB; Kitzman DW; Kleber FX; Shah SJ;
    JACC Heart Fail; 2023 Aug; 11(8 Pt 2):1103-1117. PubMed ID: 36939661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial.
    Litwin SE; Komtebedde J; Seidler T; Borlaug BA; Winkler S; Solomon SD; Eicher JC; Mazimba S; Khawash R; Sverdlov AL; Hummel SL; Bugger H; Boenner F; Hoendermis E; Cikes M; Demers C; Silva G; van Empel V; Starling RC; Penicka M; Cutlip DE; Leon MB; Kitzman DW; van Veldhuisen DJ; Shah SJ;
    Eur J Heart Fail; 2024 Jan; 26(1):177-189. PubMed ID: 37989800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No-Implant Interatrial Shunt for HFpEF: 6-Month Outcomes From Multicenter Pilot Feasibility Studies.
    Udelson JE; Barker CM; Wilkins G; Wilkins B; Gooley R; Lockwood S; Potter BJ; Meduri CU; Fail PS; Solet DJ; Feldt K; Kriegel JM; Shaburishvili T
    JACC Heart Fail; 2023 Aug; 11(8 Pt 2):1121-1130. PubMed ID: 37115132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
    Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction.
    Kaye DM; Hasenfuß G; Neuzil P; Post MC; Doughty R; Trochu JN; Kolodziej A; Westenfeld R; Penicka M; Rosenberg M; Walton A; Muller D; Walters D; Hausleiter J; Raake P; Petrie MC; Bergmann M; Jondeau G; Feldman T; Veldhuisen DJ; Ponikowski P; Silvestry FE; Burkhoff D; Hayward C
    Circ Heart Fail; 2016 Dec; 9(12):e003662. PubMed ID: 27852653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.
    Del Trigo M; Bergeron S; Bernier M; Amat-Santos IJ; Puri R; Campelo-Parada F; Altisent OA; Regueiro A; Eigler N; Rozenfeld E; Pibarot P; Abraham WT; Rodés-Cabau J
    Lancet; 2016 Mar; 387(10025):1290-7. PubMed ID: 27025435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction.
    Kaye DM; Petrie MC; McKenzie S; Hasenfuβ G; Malek F; Post M; Doughty RN; Trochu JN; Gustafsson F; Lang I; Kolodziej A; Westenfeld R; Penicka M; Rosenberg M; Hausleiter J; Raake P; Jondeau G; Bergmann MW; Spelman T; Aytug H; Ponikowski P; Hayward C;
    ESC Heart Fail; 2019 Feb; 6(1):62-69. PubMed ID: 30311437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction.
    Wessler J; Kaye D; Gustafsson F; Petrie MC; Hasenfuβ G; Lam CSP; Borlaug BA; Komtebedde J; Feldman T; Shah SJ; Burkhoff D;
    Circ Heart Fail; 2018 Aug; 11(8):e004540. PubMed ID: 30354556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results.
    Urey MA; Hibbert B; Jorde U; Eckman P; Simard T; Labinaz M; Nazer B; Wiley M; Gupta B; Sauer A; Shah H; Sorajja P; Pineda AM; Missov E; Mahmud E; Kahwash R; Lilly S; Latib A; Murthy S; Fam N; Garcia S; Chung ES; Klein L; Cheng R; Houston BA; Amoroso NS; Chang L; Gafoor S; Chaudhry SP; Hermiller J; Schwartz JG; Aldaia L; Koulogiannis K; Gray WA; Zahr F
    Eur J Heart Fail; 2024 Apr; 26(4):1065-1077. PubMed ID: 38606485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction.
    Patel RB; Reddy VY; Komtebedde J; Wegerich SW; Sekaric J; Swarup V; Walton A; Laurent G; Chetcuti S; Rademann M; Bergmann M; McKenzie S; Bugger H; Bruno RR; Herrmann HC; Nair A; Gupta DK; Lim S; Kapadia S; Gordon R; Vanderheyden M; Noel T; Bailey S; Gertz ZM; Trochu JN; Cutlip DE; Leon MB; Solomon SD; van Veldhuisen DJ; Auricchio A; Shah SJ
    JACC Heart Fail; 2023 Oct; 11(10):1351-1362. PubMed ID: 37480877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interatrial Shunting for Heart Failure: Early and Late Results From the First-in-Human Experience With the V-Wave System.
    Rodés-Cabau J; Bernier M; Amat-Santos IJ; Ben Gal T; Nombela-Franco L; García Del Blanco B; Kerner A; Bergeron S; Del Trigo M; Pibarot P; Shkurovich S; Eigler N; Abraham WT
    JACC Cardiovasc Interv; 2018 Nov; 11(22):2300-2310. PubMed ID: 30391390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.